Search results for "GLP-1"

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts are calling for structured...
Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

A recent observational study indicates that individuals taking popular GLP-1 receptor agonist obesity medications may face an elevated risk of...
Can Eggs and Olive Oil Help You Lose Weight? Why the

Can Eggs and Olive Oil Help You Lose Weight? Why the "Natural Wegovy" Trend Can Backfire

A viral diet trend touting olive oil drizzled over boiled eggs as a "natural Wegovy" has gained traction among...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are...
JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical Files for Phase 3 Trial of Biweekly Obesity Drug Bofanglutide

JW Pharmaceutical announced on Aug. 18 that it has submitted an Investigational New Drug application to South Korea’s...
'Natural Wegovy' Is a Myth, Surgeon Warns, Pushing Back on Viral Diet Trend

'Natural Wegovy' Is a Myth, Surgeon Warns, Pushing Back on Viral Diet Trend

A viral social media trend promoting a "Natural Wegovy" diet—eating boiled eggs drizzled with olive oil—has prompted a...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal

Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market

The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...